Detection of Clonal Aberrations by Cytogenetic Analysis after Different Culture Methods and by FISH in 129 Patients with Chronic Lymphocytic Leukemia

Jenderny, J.; Goldmann, Claudia; Thede, Rebekka; Ebrecht, Monika; Korioth, Frank

doi:10.1159/000369543

Cited by 8 publications

(3 citation statements)

References 23 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of these effective immunostimulatory agents is DSP30. Recent studies have shown the efficacy of DSP30 on CLL cells either alone or with another agent (IL-2) [17][18][19][20][21][22] .…”

Section: Discussionmentioning

confidence: 99%

“…Other chromosomal abnormalities we determined are shown in Table 1 and common abnormalities diagnosed in CLL causing bad prognosis such as t 11;14 (q13;q32) [25][26][27] , dup 12 (q13q22), t 14;19 (q32;q13.1) accompanying with +12 and add 14 (q32) [26][27][28] were also present in our study. [17][18][19][20] . We investigated 13q14.3 deletion with both conventional karyotyping and iFISH techniques.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Investigation of 13q14.3 deletion by cytogenetic analysis and FISH technique and miRNA-15a and miRNA-16-1 by real time PCR in chronic lymphocytic leukemia

Kuru¹,

Erdoğan²,

Soysal³

et al. 2022

Afr H. Sci.

View full text Add to dashboard Cite

Background: The most frequent cytogenetic aberration is 13q14.3 deletion in Chronic Lymphocytic Leukemia (CLL). HsamiR-15a/hsa-miR-16-1 are tumor suppressor miRNAs encoded from 13q14.3 region. Objectives: The aim of this study was to investigate the 13q14.3 deletion using molecular and cytogenetic techniques and association with miRNA-15a/miRNA-16-1. Materials And Methods: We used peripheral blood samples of 30 CLL patients who were either induced and or non-induced with DSP30+IL-2 to determine 13q14.3 deletion by karyotyping and iFISH. Expression levels of hsa-miR-15a/miR-16-1 were measured using qRT PCR and compared with deletions. Results: 13q14.3 deletion was detected in 8.6% of cases by karyotyping and in 65% by iFISH. Mosaic forms (monoallelic+biallelic) were observed in 50% of cases. Besides determining common chromosome abnormalities such as add(2)(q37), t(2;7) (p11.2;q22), del(6)(q13q21), del(6)(q25), add(9)(q21), del(11)(q23), t(11;14)(q13;q32), del(13)(q11q12), del(13)(q12q14), add(14)(q23), del(14)(q23), t(14;19)(q32;q13.1), del(15)(q23), del(17)(p12), t(18;22)(q21;q11.2), add(21)(p13) and t(17;21)(q11.2;122), we also determined t(1;13)(q32;q34), inv(2)(p25q21), del(13)(q22q32), t(14;19) (q24;q13), dup(17)(q21q23), der(21;21)(p13;p13) which have not been reported previously. Mitotic index data was found statistically significant and DSP30+IL-2 increased mitotic index by 2.5 folds. Association between decreased miR-16-1 expression and deletions was statistically significant. Conclusion: We suggest that cytogenetic and iFISH analyses are complementary and use of DSP30+IL-2 is effective .in CLL. Decreased expression of hsa-miR-16-1 is remarkable. Keywords: CLL; miR-15a/miR-16-1; 13q14.3 deletion.

show abstract

“…One of these effective immunostimulatory agents is DSP30. Recent studies have shown the efficacy of DSP30 on CLL cells either alone or with another agent (IL-2) [17][18][19][20][21][22] .…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Investigation of 13q14.3 deletion by cytogenetic analysis and FISH technique and miRNA-15a and miRNA-16-1 by real time PCR in chronic lymphocytic leukemia

Kuru¹,

Erdoğan²,

Soysal³

et al. 2022

Afr H. Sci.

View full text Add to dashboard Cite

show abstract

“…Jenderny et al 19 studied different variants of cultures in the group of 129 patients with CLL. They were observing the number of metaphases obtained in cell cultures conducted in parallel: both unstimulated and stimulated (with the addition of pokeweed extract (PWM) to the medium and DSP30+IL2).…”

Section: Discussionmentioning

confidence: 99%

Detection of Chromosomal Changes in Chronic Lymphocytic Leukemia Using Classical Cytogenetic Methods and Fish: Application of Rich Mitogen Mixtures for Lymphocyte Cultures

Koczkodaj

Popek

Zmorzyński

et al. 2016

Journal of Investigative Medicine

View full text Add to dashboard Cite

One of the research methods of prognostic value in chronic lymphocytic leukemia (CLL) is cytogenetic analysis. This method requires the presence of appropriate B-cell mitogens in cultures in order to obtain a high mitotic index. The aim of our research was to determine the most effective methods of in vitro B-cell stimulation to maximize the number of metaphases from peripheral blood cells of patients with CLL for classical cytogenetic examination, and then to correlate the results with those obtained using fluorescence in situ hybridization (FISH). The study group involved 50 consecutive patients with CLL. Cell cultures were maintained with the basic composition of culture medium and addition of respective stimulators. We used the following stimulators: Pokeweed Mitogen (PWM), 12-O-tetradecanoylphorbol 13-acetate (TPA), ionophore, lipopolysaccharide (LPS), and CpG-oligonucleotide DSP30. We received the highest mitotic index when using the mixture of PWM+TPA+I+DSP30. With classical cytogenetic tests using banding techniques, numerical and structural aberrations of chromosomes were detected in 46 patients, and no change was found in only four patients. Test results clearly confirmed the legitimacy of using cell cultures enriched with the mixture of cell stimulators and combining classical cytogenetic techniques with the FISH technique in later patient diagnosing.

show abstract

DSP30 and interleukin‐2 as a mitotic stimulant in B‐cell disorders including those with a low disease burden

Dun

Riley

Diano

et al. 2018

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Chromosome abnormalities detected during cytogenetic investigations for B-cell malignancy offer prognostic information that can have wide ranging clinical impacts on patients. These impacts may include monitoring frequency, treatment type, and disease staging level. The use of the synthetic oligonucleotide DSP30 combined with interleukin 2 (IL2) has been described as an effective mitotic stimulant in B-cell disorders, not only in chronic lymphocytic leukemia (CLL) but also in a range of other B-cell malignancies. Here, we describe the comparison of two B-cell mitogens, lipopolysaccharide (LPS), and DSP30 combined with IL2 as mitogens in a range of common B-cell disorders excluding CLL. The results showed that DSP30/IL2 was an effective mitogen in mature B-cell disorders, revealing abnormal cytogenetic results in a range of B-cell malignancies. The abnormality rate increased when compared to the use of LPS to 64% (DSP30/IL2) from 14% (LPS). In a number of cases the disease burden was proportionally very low, less than 10% of white cells. In 37% of these cases, the DSP30 culture revealed abnormal results. Importantly, we also obtained abnormal conventional cytogenetics results in 3 bone marrow cases in which immunophenotyping showed an absence of an abnormal B-cell clone. In these cases, the cytogenetics results correlated with the provisional diagnosis and altered their staging level. The use of DSP30 and IL2 is recommended for use in many B-cell malignancies as an effective mitogen and their use has been shown to enable successful culture of the malignant clone, even at very low levels of disease.

show abstract

Detection of Clonal Aberrations by Cytogenetic Analysis after Different Culture Methods and by FISH in 129 Patients with Chronic Lymphocytic Leukemia

Cited by 8 publications

References 23 publications

Investigation of 13q14.3 deletion by cytogenetic analysis and FISH technique and miRNA-15a and miRNA-16-1 by real time PCR in chronic lymphocytic leukemia

Investigation of 13q14.3 deletion by cytogenetic analysis and FISH technique and miRNA-15a and miRNA-16-1 by real time PCR in chronic lymphocytic leukemia

Detection of Chromosomal Changes in Chronic Lymphocytic Leukemia Using Classical Cytogenetic Methods and Fish: Application of Rich Mitogen Mixtures for Lymphocyte Cultures

DSP30 and interleukin‐2 as a mitotic stimulant in B‐cell disorders including those with a low disease burden

Contact Info

Product

Resources

About